Home
University of Bergen
Camilla Tøndel's picture

Camilla Tøndel

Associate Professor
Department of Clinical Science
  • E-mailCamilla.Tondel@uib.no
  • Phone+47 924 68 362
  • Visitor Address
    Haukeland universitetssykehus, Laboratoriebygget
    5009 Bergen
  • Postal Address
    Postboks 7804
    5020 Bergen

Camilla Tøndel has since licensing of Fabry-specific treatment in 2001 been responsible for follow-up of children and adults with Fabry disease, and in 2013 she finalised her PhD on evaluation of kidney disease and enzyme replacement therapy in Fabry disease. Renal biopsies and GFR measurements are important in many of the investigator initiated and pharmaindustry initiated studies she participates in, included GMO-based first-in-human research. Pharmacokinetics in clinical trials and as tool in evaluation of renal function (iohexol clearance) is central in her research, as also immunologic mechanisms and treatments within various organ systems/diseases. As part of the board in NorCRIN (since 2012) and NorPedMed (since 2014) she works for more clinical trials in Norway.

MED9: Chair of the MED9-board.                                                                                                      General Pediatrics. Pediatric nephrology and rheumatology.

GCP901: ICH-Good Clinical Practice

MEDMET1: ICH-Good Clinical Practice

 

Academic article
  • Show author(s) (2022). Reduced α-galactosidase A activity in zebrafish (Danio rerio) mirrors distinct features of Fabry nephropathy phenotype. Molecular Genetics and Metabolism Reports. 1-11.
  • Show author(s) (2022). A novel unbiased method reveals progressive podocyte globotriaosylceramide accumulation and loss with age in females with Fabry Disease. Kidney International.
  • Show author(s) (2021). Standardising clinical outcomes measures for adult clinical trials in Fabry disease: A global Delphi consensus. Molecular Genetics and Metabolism. 234-243.
  • Show author(s) (2021). Randomised controlled trial showed long-term efficacy, immunogenicity and safety of varicella vaccines in Norwegian and Swedish children. Acta Paediatrica. 391-400.
  • Show author(s) (2021). Pharmacokinetics and Safety of Single-dose Tedizolid Phosphate in Children 2 to <12 Years of Age. The Pediatric Infectious Disease Journal. 317-323.
  • Show author(s) (2021). Low birthweight is associated with lower glomerular filtration rate in middle-aged mainly healthy women. Nephrology, Dialysis and Transplantation. 92-99.
  • Show author(s) (2021). Long COVID in a prospective cohort of home-isolated patients. Nature Medicine. 1607-1613.
  • Show author(s) (2021). Efficacy and safety of mirabegron in children and adolescents with neurogenic detrusor overactivity: An open‐label, phase 3, dose‐titration study. Neurourology and Urodynamics.
  • Show author(s) (2021). Early start of enzyme replacement therapy in pediatric male patients with classical Fabry disease is associated with attenuated disease progression. Molecular Genetics and Metabolism. 1-7.
  • Show author(s) (2021). Cardiovascular changes in young renal failure patients. Clinical Kidney Journal (CKJ).
  • Show author(s) (2021). Attack rates amongst household members of outpatients with confirmed COVID-19 in Bergen, Norway: A case-ascertained study. The Lancet Regional Health - Europe. 9 pages.
  • Show author(s) (2021). Accuracy of single intravenous access iohexol GFR in children is hampered by marker contamination. Scientific Reports. 7 pages.
  • Show author(s) (2020). SARS-CoV-2-specific neutralizing antibody responses in Norwegian healthcare workers after the first wave of COVID-19 pandemic: a prospective cohort study. Journal of Infectious Diseases.
  • Show author(s) (2020). Growth Differentiation Factor 15 in Children with Chronic Kidney Disease and after Renal Transplantation. Disease Markers. 1-8.
  • Show author(s) (2020). Early Induction of Cross-Reactive CD8+ T-Cell Responses in Tonsils After Live-Attenuated Influenza Vaccination in Children. Journal of Infectious Diseases. 1528-1537.
  • Show author(s) (2020). Accumulation of Globotriaosylceramide in Podocytes in Fabry Nephropathy Is Associated with Progressive Podocyte Loss. Journal of the American Society of Nephrology. 865-875.
  • Show author(s) (2019). The pharmacokinetics, safety, and tolerability of mirabegron in children and adolescents with neurogenic detrusor overactivity or idiopathic overactive bladder and development of a population pharmacokinetic model-based pediatric dose estimation. Journal of Pediatric Urology.
  • Show author(s) (2019). Measurement of renal functional response using iohexol clearance-A study of different outpatient procedures. Clinical Kidney Journal (CKJ). 181-188.
  • Show author(s) (2019). Low-dose agalsidase beta treatment in male pediatric patients with Fabry disease: A 5-year randomized controlled trial. Molecular Genetics and Metabolism. 86-94.
  • Show author(s) (2018). The effect of enzyme replacement therapy on clinical outcomes in paediatric patients with Fabry disease - A systematic literature review by a European panel of experts. Molecular Genetics and Metabolism. 1-12.
  • Show author(s) (2018). Estimating glomerular filtration rate in children: evaluation of creatinine- and cystatin C-based equations. Pediatric nephrology (Berlin, West). 1-11.
  • Show author(s) (2018). Effects of nutritional Vitamin D supplementation on markers of bone and mineral metabolism in children with chronic kidney disease. Nephrology, Dialysis and Transplantation. 2208-2217.
  • Show author(s) (2017). Renal Function Influences Diagnostic Markers in Serum and Urine: A Study of Guanidinoacetate, Creatine, Human Epididymis Protein 4, and Neutrophil Gelatinase–Associated Lipocalin in Children. The Journal of Applied Laboratory Medicine. 297-308.
  • Show author(s) (2017). Pathomechanisms of renal Fabry disease. Cell and Tissue Research. 53-62.
  • Show author(s) (2017). Long-term dose-dependent agalsidase effects on kidney histology in fabry disease. American Society of Nephrology. Clinical Journal. 1470-1479.
  • Show author(s) (2017). Iohexol plasma clearance in children: validation of multiple formulas and single-point sampling times. Pediatric nephrology (Berlin, West). 1-14.
  • Show author(s) (2017). Hearing loss in children with Fabry disease. The Journal of Inherited Metabolic Disease (JIMD). 725-731.
  • Show author(s) (2017). Bedside stereomicroscopy of Fabry kidney biopsies: An easily available method for diagnosis and assessment of sphingolipid deposits. Nephron. 13-21.
  • Show author(s) (2016). Reaccumulation of globotriaosylceramide in podocytes after agalsidase dose reduction in young Fabry patients. Nephrology, Dialysis and Transplantation. 807-813.
  • Show author(s) (2016). One Year of Enzyme Replacement Therapy Reduces Globotriaosylceramide Inclusions in Podocytes in Male Adult Patients with Fabry Disease. PLOS ONE.
  • Show author(s) (2016). Live attenuated influenza vaccine in children induces b-cell responses in tonsils. Journal of Infectious Diseases. 722-731.
  • Show author(s) (2016). Iohexol plasma clearance in children: validation of multiple formulas and two-point sampling times. Pediatric nephrology (Berlin, West). 311-320.
  • Show author(s) (2015). Recommendations for initiation and cessation of enzyme replacement therapy in patients with Fabry disease: The European Fabry Working Group consensus document. Orphanet Journal of Rare Diseases. 1-10.
  • Show author(s) (2015). Longevity of B-cell and T-cell responses after live attenuated influenza vaccination in children. Journal of Infectious Diseases. 1541-1549.
  • Show author(s) (2015). Glomerular filtration rate measured by iohexol clearance: A comparison of venous samples and capillary blood spots. Scandinavian Journal of Clinical and Laboratory Investigation. 710-716.
  • Show author(s) (2015). Foot process effacement is an early marker of nephropathy in young classic fabry patients without albuminuria. Nephron. 16-21.
  • Show author(s) (2015). Chronic kidney disease and an uncertain diagnosis of Fabry disease: approach to a correct diagnosis. Molecular Genetics and Metabolism. 242-247.
  • Show author(s) (2015). Characterization of early disease status in treatment-naive male paediatric patients with fabry disease enrolled in a randomized clinical trial. PLOS ONE.
  • Show author(s) (2014). Uncertain diagnosis of fabry disease in patients with neuropathic pain, angiokeratoma or cornea verticillata: consensus on the approach to diagnosis and follow-up. JIMD Reports. 83-90.
  • Show author(s) (2014). Mosaicism of podocyte involvement is related to podocyte injury in females with Fabry disease. PLOS ONE.
  • Show author(s) (2013). Agalsidase Benefits Renal Histology in Young Patients with Fabry Disease. Journal of the American Society of Nephrology. 137-148.
  • Show author(s) (2012). Safety and complications of percutaneous kidney biopsies in 715 children and 8573 adults in Norway 1988-2010. American Society of Nephrology. Clinical Journal. 1591-1597.
  • Show author(s) (2012). Recommendations on Reintroduction of Agalsidase Beta for Patients with Fabry Disease in Europe, Following a Period of Shortage. JIMD Reports.
  • Show author(s) (2011). Progressive podocyte injury and globotriaosylceramide (GL-3) accumulation in young patients with Fabry disease. Kidney International. 663-670.
  • Show author(s) (2010). Monitoring renal function in children with Fabry disease: comparisons of measured and creatinine-based estimated glomerular filtration rate. Nephrology, Dialysis and Transplantation. 1507-1513.
  • Show author(s) (2010). Modelling the resource implications of managing adults with Fabry disease in Norway favours home infusion. European Journal of Clinical Investigation. 1104-1112.
  • Show author(s) (2009). The MDRD equation may mask decline of glomerular filtration rate in Fabry patients with normal or nearly normal kidney function. Clinical Nephrology. 118-124.
  • Show author(s) (2009). Monitoring renal Function in Fabry children: comparisons of measured and creatinine-based estimated Glomerular Filtration Rate. Nephrology, Dialysis and Transplantation. 7 pages.
  • Show author(s) (2008). Renal biopsy findings in children and adolescents with Fabry disease and minimal albuminuria. American Journal of Kidney Diseases. 767-776.
  • Show author(s) (2005). Focal and segmental glomerular sclerosis (FSGS) in a man and a woman with Fabry's disease. Clinical Nephrology. 394-401.
  • Show author(s) (2003). [Intravenous Enzyme Substitution Therapy in Children With Fabry's Disease] . Tidsskrift for Den norske legeforening.
  • Show author(s) (2002). Behandling av Graves sykdom hos barn og unge. Pediatrisk Endokrinologi. 42-46.
Academic lecture
  • Show author(s) (2021). Cleared Podocytes and Normal Kidney Function in Classical Fabry Males 15 Years After Start of Enzyme Replacement Therapy at Young Age.
  • Show author(s) (2019). Fabry Nephropathy: First mRNA-seq Findings from Kidney Biopsies Before and After Enzyme Replacement Therapy.
  • Show author(s) (2015). Cellular immune responses after live attenuated influenza vaccination in children, a clinical trial.
  • Show author(s) (2013). Podocytes: Therapeutic Target in Fabry Disease?
  • Show author(s) (2010). 5 YEARS FOLLOW-UP RENAL BIOPSIES IN PAEDIATRIC AND ADULT FABRY PATIENTS ON ENZYME REPLACEMENT THERAPY.
  • Show author(s) (2009). Corneal changes in Fabry's disease.
Reader opinion piece
  • Show author(s) (2013). Small fibre neuropathy in Fabry disease. Journal of Neurology. 917-919.
  • Show author(s) (2011). Fabry or not Fabry – a question of ascertainment. European Journal of Human Genetics. 1111-1112.
Doctoral dissertation
  • Show author(s) (2020). Estimation and measurement of glomerular filtration rate in children.
  • Show author(s) (2017). Hereditary renal disease in the Norwegian population, with a focus on Fabry disease.
  • Show author(s) (2013). Markers of nephropathy in young Fabry disease patients; role of kidney biopsies and functional measurement.
Interview
  • Show author(s) (2022). Lovende resultater av mulig ny behandling av Fabry sykdom: – Stor praktisk betydning.
  • Show author(s) (2022). Katrine (47) har meldt seg frivillig til å teste en ny, norsk vaksine. Håpet er at den skal beskytte lenger enn de man har hatt til nå .
  • Show author(s) (2021). Her settes første dose av norskutviklet koronavaksine.
  • Show author(s) (2015). Kreft hos barn og betydning av klinisk utprøving hos barn.
  • Show author(s) (2015). Har testet medisiner på 400 barn.
  • Show author(s) (2014). Kampen mot kreft.
  • Show author(s) (2014). Forskning på legemidler til barn må gjøres i Norge.
  • Show author(s) (2013). Forskning på medisiner til barn, Ekko .
  • Show author(s) (2013). Enzyme replacement in Fabry disease.
Programme participation
  • Show author(s) (2015). Liv og død-serien; Legemiddelutprøving hos barn.
Abstract
  • Show author(s) (2013). Renal structural-functional relationship (SFR) studies suggest that podocyte GL-3 accumulation predicts urine protein creatinine ratio in Fabry disease (FD) nephropathy (FDN). Molecular Genetics and Metabolism. S68-S69.
  • Show author(s) (2013). GLOMERULAR FILTRATION RATE (GFR) MEASURED BY IOHEXOL CLEARANCE IN CHILDREN; A COMPARISON BETWEEN VENOUS SAMPLES AND DRIED BLOOD SPOTS. Pediatric nephrology (Berlin, West). 1653-1654.
  • Show author(s) (2013). A randomized, multicenter, multinational, phase 3B, open-label, parallel-group study of agalsidase beta in treatment-naive male pediatric patients with Fabry disease without severe symptoms: Baseline demographics and clinical data. Molecular Genetics and Metabolism. S99-S99.
  • Show author(s) (2012). Mosaicism of Podocyte Involvement in Untreated Females with Fabry Disease. Molecular Genetics and Metabolism. S47-S48.
  • Show author(s) (2010). RENAL FOLLOW-UP BIOPSIES IN YOUNG MALE FABRY PATIENTS ON ENZYME REPLACEMENT THERAPY. Clinical Therapeutics. S105-S107.
  • Show author(s) (2009). Monitoring renal Function in Fabry children; estimated or measured glomerular Filtration rate? Molecular Genetics and Metabolism. 74-75.
  • Show author(s) (2009). Fabry Disease: Unusual Symptoms in two Boys Treated with Lamotrigine and Fabrazyme, Respectively. Clinical Therapeutics. S43-S43.
  • Show author(s) (2008). Prominence of glomerular and vascular changes in renal biopsies in children and adolescents with Fabry disease and microalbuminuria. Clinical Therapeutics. S42-S42.
Poster
  • Show author(s) (2022). Safety and efficacy of pegunigalsidase alfa administered every 4 weeks in patients with Fabry disease: Results from the phase 3, open-label, BRIGHT study.
  • Show author(s) (2022). Globotriaosylceramide (GL3) accumulation in Fabry podocytes in female patients is progressive with age and associated with podocyte loss and proteinuria.
  • Show author(s) (2021). Synuclein Alpha Accumulation Drives Lysosomal Dysfunction in Fabry Podocytopathy.
  • Show author(s) (2021). Pharmacokinetics, Safety, and Tolerability of Imipenem/Cilastatin/Relebactam in Pediatric Participants With Confirmed or Suspected Gram-negative Bacterial Infections: A Phase 1b, Open-label, Single-dose Clinical Trial.
  • Show author(s) (2020). Systems Analyses of Renal Fabry Transcriptome and Response to Enzyme Replacement Therapy (ERT) Identifies a Cross-Validated and Druggable ERT-Resistant Module.
  • Show author(s) (2020). Switching from agalsidase alfa to pegunigalsidase alfa for treating Fabry disease: One year of treatment data from BRIDGE, a phase III open label study .
  • Show author(s) (2020). Switching from Agalsidase Alfa to Pegunigalsidase Alfa for Treating Fabry Disease: One Year of Treatment Data from Bridge, a Phase 3 Open-Label Study.
  • Show author(s) (2020). Low Birth Weigth Is Associated With Lower Measured Glomerular Filtration Rate In Adult Age.
  • Show author(s) (2020). Diagnosis of AKI using Iohexol in critically ill children and neonates: preliminary results of the HERO study.
  • Show author(s) (2019). Prelimenary Results of the Fabry Disease Phase III Open Label Study of Switching from Agalsidase Alfa to Pegunigalsidase Alfa.
  • Show author(s) (2019). Pegunigalsidase alfa for the treatment of Fabry disease - Phase III open label, switch over study from agalsidase alfa - Preliminary results.
  • Show author(s) (2019). Once every 4 weeks 2 mg/kg of pegunigalsidase alfa for treating Fabry disease- preliminary result of a phase 3 study.
  • Show author(s) (2019). New Regimen of Once Every 4 Weeks 2 mg/kg of Pedunigalsidase Alfa for Treating Fabry Disease - Prelimenary Results of a Phase 3 Study.
  • Show author(s) (2019). Measurement of renal functional response using iohexol clearance.
  • Show author(s) (2019). Clinical Consequences of Paired Cardiac and Kidney Biopsies in a Treatment Naive Female Fabry Patient with a Classical Mutation and Minor Clnical Symptoms.
  • Show author(s) (2019). Analysis of the baseline characteristics of Fabry disease patients screened for the pegunigalsidase alfa Phase III BALANCE study .
  • Show author(s) (2019). Accumulation of Globotriaosylceramide in Podocytes (PC) in Fabry Nephropathy Is Associated with Progressive PC Loss.
  • Show author(s) (2018). SINGLE INTRAVENOUS ACCESS FOR MEASUREMENT OF GLOMERULAR FILTRATION RATE IN CHILDREN AFTER MARKER INJECTION.
  • Show author(s) (2018). Podocyte structural parameters predict glomerular filtration rate (GFR) loss in male patients with classic Fabry disease.
  • Show author(s) (2018). KIDNEY-SPECIFIC THERAPEUTIC GOALS FOR FABRY DISEASE BASED ON EUROPEAN EXPERT CONSENSUS RECOMMENDATIONS AND SYSTEMATIC REVIEW OF PUBLISHED EVIDENCE.
  • Show author(s) (2018). IOHEXOL CLEARANCE IN CHILDREN WITH LOW GFR: COMPARISON OF 24 HOURS SINGLE-POINT GFR AND MULTIPLE-POINT GFR.
  • Show author(s) (2018). Fabry nephropathy: Transcriptome sequencing of microdissected renal compartments from archival kidney biopsies at baseline, and after 5 & 10 years of enzyme replacement therapy.
  • Show author(s) (2017). Single-point iohexol plasma clearance in children: validation of multiple formulas and sampling times.
  • Show author(s) (2017). Simplified Clinical Pre-histologic Scoring Method of Kidney Biopsies in Fabry Disease.
  • Show author(s) (2017). Podocyte globotriaosylceramide (GL-3) content strongly impacts age-dependent podocyte loss in ERT-naïve male Fabry patients.
  • Show author(s) (2017). A randomized, phase 3B, open-label, parallel-group study of agalsidase beta in treatment-naive male pediatric patients with Fabry disease without severe symptoms (FIELD study): GL-3 clearance from superficial skin capillary endothelium.
  • Show author(s) (2017). A randomized, phase 3B, open-label, parallel-group study of agalsidase beta in treatment-naive male pediatric patients with Fabry disease without severe symptoms (FIELD study): GL-3 clearance from kidney cells.
  • Show author(s) (2016). Podocyte Hypertrophy and Globotriaosylceramide (GL-3) Accumulation Are Strong Predictors of Podocyte Loss in Enzyme Replacement Therapy Naïve Male Patients with Fabry Disease.
  • Show author(s) (2016). Glomerular filtration rate (GFR) strongly influences guanidinoacetic acid (GAA) in plasma and urine.
  • Show author(s) (2016). GDF-15 in plasma and urine as a marker of kidney function in children .
  • Show author(s) (2016). Differential response of glomerular parietal epithelial cells and podocytes to enzyme replacement therapy in Fabry nephropathy.
  • Show author(s) (2015). Podocyte Globotriaosylceramide (GL3) Accumulation in Fabry Disease Is Influenced by Age and Genotype .
  • Show author(s) (2015). LONG-TERM ENZYME REPLACEMENT THERAPY (ERT) BENEFITS THE GLOMERULI MORE THAN THE VASCULATURE IN YOUNGER FABRY NEPHROPATHY .
  • Show author(s) (2015). FABRY DISEASE DIAGNOSED IN LIVING DONOR KIDNEY TRANSPLANT BIOPSY.
  • Show author(s) (2015). DIFFERENTIAL KIDNEY EFFECTS OF HIGH AND LOW ENZYME DOSE IN MALE SIBLINGS TREATED FOR 13 YEARS .
  • Show author(s) (2014). Renal Biopsies after 6-11 Years of Enzyme Replacement Therapy in 9 Young Classic Fabry Disease Patients.
  • Show author(s) (2014). Five Children with Fabry Disease and Significant Tissue Damage in Renal Biopsies Despite Normal Clinical Renal Parameters.
  • Show author(s) (2014). Fabry nephropathy (FN) outcome and the impact of diagnostic kidney biopsies after 10 years enzyme replacement therapy (ERT).
  • Show author(s) (2014). Enzyme Replacement Therapy (ERT) in Fabry Disease (FD) Reduces Podocyte (PC) Globotriaosylceramide (GL3) Content within a Year (yr).
  • Show author(s) (2014). Consensus recommendation on Fabry disease diagnosis in adult patients with kidney disease.
  • Show author(s) (2013). Glomerular filtration rate (GFR) measured by iohexolclearance in children; how many sample points are necessary?
  • Show author(s) (2013). Glomerular Filtration Rate (GFR) measured by Iohexol Clearance in Children; a comparison between venous samples and dried spots.
  • Show author(s) (2009). Renal follow-up biopsies in young male Fabry patients on enzyme replacement therapy.
  • Show author(s) (2008). Renal biopsies in children in Norway 1988-2005: clinical variables, complications and prognosis.
  • Show author(s) (2008). Formula GFR overestimates Renal Function in Children and Adult Males with Fabry Disease and Stage 1-2 CKD.
  • Show author(s) (2008). Fabry disease: Unusual symptoms in two male children treated with lamotrigine and fabrazyme, respectively.
Errata
  • Show author(s) (2016). Erratum to: Iohexol plasma clearance in children: validation of multiple formulas and two-point sampling times (Pediatric Nephrology, (2017), 32, 2, (311-320), 10.1007/s00467-016-3436-z). Pediatric nephrology (Berlin, West). 375-376.
Academic literature review
  • Show author(s) (2018). European expert consensus statement on therapeutic goals in Fabry disease. Molecular Genetics and Metabolism. 189-203.

More information in national current research information system (CRIStin)

Research groups